Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers [0.03%]
AT-rich互作域1A突变癌症的临床和突变特征
Rosa Falcone,Marco Filetti,Pasquale Lombardi et al.
Rosa Falcone et al.
Aim: AT-rich interaction domain 1A (ARID1A) encodes a key component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex that participates in gene expression. ARID1A alterations are quite common am...
In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer [0.03%]
计算靶向集落刺激因子-1受体：癌症免疫治疗的策略与展望
Zahra Azhar,Richard P Grose,Afsheen Raza et al.
Zahra Azhar et al.
Aim: Delineate structure-based inhibition of colony-stimulating factor-1 receptor (CSF1R) by small molecule CSF1R inhibitors in clinical development for target identification and potential lead optimization in cancer ther...
Protein ISGylation: a posttranslational modification with implications for malignant neoplasms [0.03%]
蛋白质ISG化：一种影响恶性肿瘤的翻译后修饰
Angeles C Tecalco-Cruz,Jesús Zepeda-Cervantes
Angeles C Tecalco-Cruz
Interferon (IFN)-stimulated gene 15 (ISG15) is a member of the ubiquitin-like (UBL) protein family that can modify specific proteins via a catalytic process called ISGylation. This posttranslational modification can modulate the stability o...
Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis [0.03%]
黄曲霉毒素B1-DNA加合物通过术后介入治疗改善肝细胞癌的预后
Liyan Huang,Qinqin Long,Qunying Su et al.
Liyan Huang et al.
Aim: DNA damage involves in the carcinogenesis of some cancer and may act as a target for therapeutic intervention of cancers. However, it is unclear whether aflatoxin B1 (AFB1)-DNA adducts (ADAs), an important kind of DN...
Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review [0.03%]
人工智能和影像组学在磁共振直肠癌影像中的应用：综述
Giuseppe Di Costanzo,Raffaele Ascione,Andrea Ponsiglione et al.
Giuseppe Di Costanzo et al.
Rectal cancer (RC) is one of the most common tumours worldwide in both males and females, with significant morbidity and mortality rates, and it accounts for approximately one-third of colorectal cancers (CRCs). Magnetic resonance imaging (...
Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells [0.03%]
葡萄糖代谢重编程促进肝癌细胞免疫逃逸
Qiuyue Zhang,Jinchen Liu,Haifeng Lin et al.
Qiuyue Zhang et al.
Hepatocellular carcinoma (HCC) is a complex process that plays an important role in its progression. Abnormal glucose metabolism in HCC cells can meet the nutrients required for the occurrence and development of liver cancer, better adapt t...
Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors [0.03%]
组蛋白去乙酰化酶8抑制剂高通量筛选的连续酶活测定法
Markus Schweipert,Anuja Amurthavasan,Franz-Josef Meyer-Almes
Markus Schweipert
Aim: Human histone deacetylase 8 (KDAC8) is a well-recognized pharmaceutical target in Cornelia de Lange syndrome and different types of cancer, particularly childhood neuroblastoma. Several classes of chemotypes have bee...
Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies [0.03%]
潜在的策略利用维生素D和某些植物化学物质增强免疫检查点阻断疗法的有效性
Ai Tsuji,Sayuri Yoshikawa,Sae Morikawa et al.
Ai Tsuji et al.
Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However, its effectiveness is limited in part due t...
An introductory review of post-resection chemotherapeutics for primary brain tumors [0.03%]
原发性脑肿瘤术后化疗药物的初步评述
Meaghan McGovern,Michaela Scanlon,Amanda Stanton et al.
Meaghan McGovern et al.
The treatment of central nervous system (CNS) tumors is complicated by high rates of recurrence and treatment resistance that contribute to high morbidity and mortality (Nat Rev Neurol. 2022;18:221-36. doi: 10.1038/s41582-022-00621-0). One ...
Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential [0.03%]
肿瘤微环境中1型和2型细胞因子介导的免疫调节及其治疗潜力
Eric Jou
Eric Jou
Cancer remains the second leading cause of death worldwide despite modern breakthroughs in medicine, and novel treatments are urgently needed. The revolutionary success of immune checkpoint inhibitors in the past decade serves as proof of c...